The Pharma Data

NOVEMBER 9, 2020

Combining ICIs with radiation therapy is emerging as a valuable strategy to “prime” an immune response and thereby increase the response rate, however the efficacy of radiation therapy is limited by toxicities related to the exposure of healthy tissues. NBTXR3 is injected one time, directly into solid tumors.

Immune Response 40

Immune Response Therapies Clinical Trials Treatment 40

The Pharma Data

OCTOBER 19, 2020

The physical and universal mode of action (MoA) of NBTXR3 is designed to trigger cellular destruction death and adaptive immune response. Promising results have been observed in the phase I trial regarding local control. About NANOBIOTIX: www.nanobiotix.com.

Clinical Trials 52

Clinical Trials Immune Response Trials Therapies 52

Drug Target Review

FEBRUARY 28, 2024

Preclinical research on γδ T cells has made great strides since the cells were first identified in the 1980s, with γδ T-cell therapies from several companies, including IN8bio, now in or nearing clinical trials for various cancers. from 2003 to 2006, covering the biotechnology and life-science tools sectors. Cells 9(40):800 (2020).

Therapies 105

Therapies Engineering Molecular Biology Immune Response 105